{"title":"Therapeutic potential of GABAA receptor subunit expression abnormalities in fragile X syndrome","authors":"Mathijs B. van der Lei, R. Kooy","doi":"10.1080/23808993.2021.2008168","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Many studies have reported brain region and age-dependent alterations in the expression of several subunits of the GABAA receptor in Fmr1 KO mice. GABAA receptors are located synaptic and extrasynaptic with differential subunit compositions and characteristics. Interestingly, the activity of many subunits of the GABAA receptor is amendable by differential pharmacological treatment. Areas Covered The purpose of this review is to summarize the expression of GABAA receptor subunits in different brain regions of Fmr1 KO mice across different ages. The decreased expression of the synaptic α2 subunit in juvenile, and the decreased expression of the extrasynaptic δ subunit in both juvenile and adult Fmr1 KO mice, are among the most consistent abnormalities reported. Both subunits are suitable for treatment and currently available compounds are discussed in this review along with their therapeutic potential. Expert Opinion Pharmacological treatment targeting specific subunits of the GABAA receptor has shown selective improvements in fragile X syndrome. To our knowledge, combinatorial therapies targeting multiple subunits of the GABAA receptor have not been explored. We here argue that such a combination therapy could induce a synergistic effect to ameliorate the clinical symptoms of fragile X syndrome.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"7 1","pages":"105 - 120"},"PeriodicalIF":1.0000,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2021.2008168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACT Introduction Many studies have reported brain region and age-dependent alterations in the expression of several subunits of the GABAA receptor in Fmr1 KO mice. GABAA receptors are located synaptic and extrasynaptic with differential subunit compositions and characteristics. Interestingly, the activity of many subunits of the GABAA receptor is amendable by differential pharmacological treatment. Areas Covered The purpose of this review is to summarize the expression of GABAA receptor subunits in different brain regions of Fmr1 KO mice across different ages. The decreased expression of the synaptic α2 subunit in juvenile, and the decreased expression of the extrasynaptic δ subunit in both juvenile and adult Fmr1 KO mice, are among the most consistent abnormalities reported. Both subunits are suitable for treatment and currently available compounds are discussed in this review along with their therapeutic potential. Expert Opinion Pharmacological treatment targeting specific subunits of the GABAA receptor has shown selective improvements in fragile X syndrome. To our knowledge, combinatorial therapies targeting multiple subunits of the GABAA receptor have not been explored. We here argue that such a combination therapy could induce a synergistic effect to ameliorate the clinical symptoms of fragile X syndrome.
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.